The business model of Kamada Ltd revolves around the development, production, and commercialization of specialty plasma-derived protein therapeutics. Kamada focuses on three main areas: respiratory diseases, AAT Deficiency, and graft-versus-host disease. By utilizing advanced technologies and expertise in protein purification, Kamada aims to provide innovative solutions for patients and healthcare professionals. With its comprehensive portfolio of FDA-approved products and strategic partnerships, Kamada strives to improve the quality of life for individuals facing these medical conditions. As a leading biopharmaceutical company, Kamada Ltd leverages its extensive knowledge and resources to bring transformative therapies to the market.

Kamada Ltd is primarily active in the biopharmaceutical industry.

The main competitors of Kamada Ltd in the market are companies like Takeda Pharmaceutical Company Limited, CSL Limited, and Grifols, S.A. These companies also operate in the biopharmaceutical industry and offer similar products and services. However, Kamada Ltd distinguishes itself through its innovative research and development efforts, strong global presence, and a diverse product portfolio. Its commitment to technological advancements and strategic partnerships enables Kamada Ltd to stay competitive and maintain a significant market position.

Kamada Ltd is a pharmaceutical company based in Israel. Founded in 1990, the company specializes in the development and production of plasma-derived protein therapeutics. With a focus on rare diseases and respiratory conditions, Kamada's innovative therapies have gained recognition globally. The company has a strong track record of successful partnerships with leading pharmaceutical companies and has expanded its market reach across Europe, the United States, and other regions. Kamada's dedication to research and development has resulted in numerous approvals from regulatory authorities, enhancing its reputation as a leader in the biopharmaceutical industry. Through its commitment to providing life-saving treatments, Kamada Ltd continues to improve the well-being of patients worldwide.

Kamada Ltd has achieved several significant milestones throughout its operation. The company demonstrated its dedication to innovation and development by receiving approval for several therapeutic products. For instance, in 2011, Kamada obtained FDA approval for Glassia, its flagship treatment for Alpha-1 Antitrypsin Deficiency. Additionally, the company successfully launched AATscan, a diagnostic tool used for detecting the presence of Alpha-1 Antitrypsin Deficiency. Furthermore, Kamada established partnerships with renowned global pharmaceutical companies, expanding its market presence and enhancing its research and development capabilities. These accomplishments highlight Kamada Ltd's commitment to advancing medical solutions and solidify their position as a leading player in the healthcare industry.

Kamada Ltd is primarily present in multiple countries and regions worldwide. With a strong global presence, the company operates in various key markets, including the United States, Canada, Europe, Israel, and Latin America. Kamada Ltd's diversified geographical footprint enables it to reach a wide range of customers and expand its distribution network effectively.

Kamada Ltd represents values of innovation, dedication, and excellence. Committed to improving patients' lives, Kamada focuses on developing and commercializing plasma-derived protein therapeutics. With a corporate philosophy centered on integrity, transparency, and ethical conduct, the company aims to deliver high-quality treatments and meet the medical needs of diverse patient populations. By prioritizing research and development initiatives, Kamada strives to leverage its scientific expertise and technological advancements to address unmet medical needs. Through collaboration and partnership, Kamada Ltd is dedicated to making a positive impact in the healthcare industry, promoting patient well-being, and advancing medical advancements.

Analysts currently set an average price target of 13,26 USD for the Kamada stock (median: 13,26 USD), implying −99,4 % versus the latest price. The consensus is based on 9 analyst ratings.

Kamada Analyytikkojen kursstavoitteet 2026

9 analysts currently rate the Kamada stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Kamada to generate revenue of 600,26 M USD and earnings per share of 0,40 USD.

Kamada Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Kamada share trades at 1 857,38 EUR (2 115,00 USD).

The Kamada share (KMDA) is listed on 2 stock exchanges, including: NASDAQ (KMDA).

Kamada Ltd. is a biopharmaceutical company based in Israel that specializes in the development, manufacturing, and marketing of products for the treatment of various diseases. The company's business model is based on its ability to produce innovative products based on proteins that are relevant for the therapy of diseases such as Alpha-1 antit... The company's main areas of focus include the production of intravenous immunoglobulins (IVIG) for the treatment of severe immunodeficiency disorders. IVIG is also used in the treatment of autoimmune diseases such as rheumatoid arthritis and lupus. Kamada is currently the only manufacturer of IVIG in Israel. The company's products are also available in Europe and the USA. Another important area of the company is the production of alpha-1 proteinase inhibitors (AAT) for the treatment of alpha-1 antitrypsin deficiency. This is an inherited disease that can lead to severe lung damage. Kamada has introduced the first AAT product manufactured in Israel to the market. It is also distributed in Europe and the USA. In addition to IVIG and AAT, Kamada also produces Factor VIII concentrates for the treatment of hemophilia and for blood clotting in patients who have received blood transfusions. The company also manufactures enzymes for the diagnosis of diseases and for research. Another business area of the company is the development of biosimilars, which mimic biological medicines that are already on the market. Kamada's biosimilars will help improve access to important therapies and relieve healthcare systems. Currently, the company is developing biosimilars for use in lung diseases and malignant diseases. Kamada's business model also includes collaboration with other companies in the biotechnology industry. The company has partnerships with leading companies such as Baxter, Shire, and Novartis to distribute or co-develop its products. In summary, Kamada's business model is focused on producing and marketing innovative products for the treatment of various diseases. The company specializes in protein production and has partnerships with other biotechnology companies. The different divisions of the company include the production of IVIG, AAT, Factor VIII concentrates, enzymes, and biosimilars. Kamada is also involved in the development of new products to meet patient needs and improve access to important therapies.

odotettu liikevaihto Kamada on 600,26 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Kamada on 24,66 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Kamada:n hinta-voitto-suhde (P/E) on tällä hetkellä 5 288,87. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Kamada-osakkeen arvostusta.

Kamada:n hinta-myynti-suhde (P/S) on tällä hetkellä 217,26. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Kamada-osakkeen arvostuskennuslukuna.

Kamada:n Eulpool-laatuscore on 5/10.

Kamada:n ISIN on IL0010941198. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Kamada:n WKN on A0JMEX. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Kamada:n ticker on KMDA. Tämä pörssinoteeraus käytetään Kamada-osakkeiden kauppaan pörssissä.

Viimeisten 12 kuukauden aikana Kamada maksoi osinkoa 0,20 USD . Tämä vastaa osingontuottoa noin 0,01 %. Tulevien 12 kuukauden aikana Kamada odotetaan maksavan osinkoa 0,20 USD.

Kamada:n nykyinen osinkotuotto on 0,01 %.

Kamada maksoi osinkoa joka vuosi viimeisten 1 vuoden aikana.

Tulevien 12 kuukauden aikana odotetaan osinkoja, joiden määrä on 0,20 USD. Tämä vastaa osingontuottoa 0,01 %.

Kamada kuuluu sektoriin 'Terveydenhuolto'.

Saadaksesi viimeisen osingon Kamada:sta päivältä määrässä 0,25 USD, sinulla piti olla osake portfoliossasi ennen irtoamispäivää .

Viimeinen osinko maksettiin .

Kamada:n osingot jaetaan valuutassa USD.